Dextromethorphan Polistirex

微量样本外泌体外泌体（exosomes）广泛存在于各种体液中，如血液、尿液、脑脊液等，并且携带有多种生物分子，包括蛋白质、核酸、脂质和小分子化合物等。了解外泌体中的这些分子有助于人们深入了解细胞间通讯、信号转导、免疫应答等生物学过程。不过对许多研究人员而言，外泌体的分析存在难度，因为要获得高纯度、高产量的外泌体往往需要足够多的样本才能满足要求。而对于本身就难以大量收集的样本（如泪液、房水、脑脊液等）来说，外泌体的分析更是难度升级。     对此，汇芯生物开发了全自动外泌体提取系统EXODUS®来解决这一难题。EXODUS®是基于负压振荡和双耦合超声振荡的新型外泌体分离技术，该方法由外泌体分离富集纳米芯片和工作站组成。工作站使EXODUS®自动化，从而简化了操作，并具有出色的稳定性和可重复性，适用于各种生物样本的标准化分离。EXODUS®全新升级让微量样本外泌体分离不再是挑战EXODUS®增加微量样本分离程序，适配小量样本管，可解决微量样本（例如泪液、房水、玻璃体等）外泌体纯化难、产量低的问题。可以快速的从微量样本中(<10 μL）分离高纯度、高产量、高生物活性的外泌体；操作简单、轻易上手、产出稳定。EXODUS®分离纯化后的外泌体可广泛用于疾病标记物的鉴定、筛选、诊断等领域。可分离微量样本类型微量样本分离操作流程注：以泪液样本为例微量样本外泌体电镜结果展示微量样本外泌体应用与研究思路EXODUS®为探索各种生物样本打开了大门，支持研究者在广泛的研究领域内开展探索。全新的EXODUS®微量样本分离纯化程序，将大大增加更多领域研究的可及性。应用案例1EXODUS®分离泪液EVs用于干眼和糖尿病视网膜病变的诊断（ACS Nano)研究背景泪液是泪腺分泌的维持眼睛正常生理活动的重要体液来源之一。通常，泪膜的体积约为5-10 μL，泪液通过血管渗透与部分血液成分相同，这表明泪膜在加深我们对眼部疾病和系统性疾病的认识方面发挥着重要作用。研究结果1.全自动外泌体提取系统EXODUS®分离泪液外泌体分离时间 (＜5 min)，总粒子数＞109particles（浓度：~1010 particles/mL），比SEC和UC高10-100倍。CD9、CD63、CD81和Alix蛋白条带显著，且没有明显的Calnexin污染。 图1：EXODUS、UC和SEC分离泪液外泌体结果对比2.外泌体的蛋白组分析用于干眼症的分类：收集并分离健康对照(HC)、干眼症(DES)和干眼病(DED)亚型，包括蒸发性干眼症(EDE)和水液缺乏型干眼症(ADDE)患者泪液的外泌体，利用蛋白质组学定量检测结合生物信息学分析手段以发现疾病生物标志物。共鉴定到904个蛋白质，干眼患者泪液中检测到426个外泌体蛋白，其中，CALML5、KRT6A和S100P可用于干眼的分类。图2：干眼症患者泪液外泌体蛋白质组组学鉴定与分析3.糖尿病和糖尿病视网膜病变中外泌体转录组学分析：选择健康对照组（HC）、糖尿病（DM）和糖尿病视网膜病变（DR）队列来评估泪液外泌体的差异。对泪液外泌体进行miRNA测序后，共鉴定到484个miRNAs（HC: 354; DM: 344; DR: 322），通过预测这些疾病相关失调的miRNA的富集通路，KEGG功能注释结果表明DM和DR含有共同的生物学通路。图3：糖尿病视网膜病变患者泪液外泌体转录组学鉴定与分析研究结论作者在这项工作中利用EXODUS®系统快速、高效提纯的泪液外泌体，实现对干眼症和干眼病亚型进行系统分析与诊断，同时该系统还可扩展到对糖尿病视网膜病变的实时诊断。该工作为基于泪液外泌体的精准医疗方案提供了新思路。应用案例2EXODUS®分离细胞外囊泡用于细胞外囊泡亚型的蛋白图谱研究（Science Advances）研究背景目前，EVs主要分为源自核内体的外泌体（exosomes ，30-150 nm），自质膜出芽形成的微囊泡（microvesicles ，150-1000 nm），以及细胞凋亡过程中释放的凋亡小体（apoptotic bodies ，200-5000 nm）。了解EV组成和生物功能的异质性对其发展为临床生物标志物和治疗载体至关重要。尽管已有诸多工作对细胞培养液、血浆和尿液来源EV亚群的分子谱进行解析，但关于泪液EV及EV亚群的人体组织学溯源和生物学网络仍有待揭示。研究结果1.EXODUS®泪液细胞外囊泡亚型分离使用EXODUS®成功分离了具有不同粒径范围、蛋白标志物及TEM形貌特征的泪液EV亚群，并将其定义为小尺寸EVs（sEVs; 20至100 nm）、中等尺寸EVs（mEVs; 100至200 nm）和大尺寸EVs（lEVs; 200至450 nm）。通过TEM成像发现中等尺寸EVs富含杯托状囊泡，其形态与外泌体特征一致。 图4：细胞外囊泡亚群分离原理及鉴定结果2.泪液细胞外囊泡不同亚型蛋白质组学检测与分析通过对38名健康受试者眼泪中EV亚群的全面蛋白质组学分析，分别从sEV、mEV和lEV组分中鉴定了1815、1829和1892种蛋白质，其中1470种蛋白质是可量化的。不出所料，在所有三个EV亚组中都发现了与囊泡介导的转运相关的蛋白质富集。参与蛋白质修饰和生物代谢过程的蛋白质，如小蛋白去除和有机氮化合物代谢过程，在sEV中相对高度丰富。与免疫反应和免疫调节功能相关的蛋白质优先富集在mEV中，而更多的质膜组装和翻译起始相关的蛋白质被包装在lEV中。通过MALDI-TOF MS建立了泪液EVs亚群指纹图谱并分析了三个亚群的差异，发现了两个差异峰(7718.88 和 14654.14)在蛋白质组学具有相同的表达模式, 猜测这两个蛋白质分别是 SPRR2D (7.9 kDa) 和 UAB52 (14.7 kDa)。有趣的是，这两个蛋白都优先包裹在中等尺寸EVs中。这两个峰值可以用作子集分类的潜在标记。图5：泪液细胞外囊泡亚群的组成和生物功能分析结果研究结论与血液一样，泪液细胞外囊泡的分离与检测也将具有广阔的应用前景。作为一种全新的外泌体分离技术, EXODUS®针对微量和稀有样本的外泌体提取具有无可比拟的优势, 有望成为眼科科研人员研究外泌体的利器，如针对不同疾病（葡萄膜炎、视神经炎、糖尿病视网膜病变、黄斑病变、眼部肿瘤等）与情绪（兴奋、压力等），探索泪液外泌体的生物信息与分子功能，通过量化外泌体分子指标，揭示疾病发生发展机制和优化精准分子诊断策略。      EXODUS®微量样本外泌体分离纯化已经实现了量的突破和质的飞跃，＜10 μL的泪液即可分离出总粒子数＞109的外泌体，轻松搞定下游检测。泪液、房水、玻璃体、脑脊液、关节液等微量样本都在EXODUS®上进行了相关测试，更多数据，以及想尝试的老师欢迎联系我们~电话：0755-61017077/+86 13728922472参考文献：1.Chen Y, Zhu Q, Cheng L, Wang Y, Li M, Yang Q, Hu L, Lou D, Li J, Dong X, Lee LP, Liu F. Exosome detection via the ultrafast-isolation system: EXODUS. Nat Methods. 2021;18(2):212-218.2.Hu L, Zhang T, Ma H, Pan Y, Wang S, Liu X, Dai X, Zheng Y, Lee LP, Liu F. Discovering the Secret of Diseases by Incorporated Tear Exosomes Analysis via Rapid-Isolation System: iTEARS. ACS Nano. 2022;16(8):11720-11732.3.Hu L, Liu X, Zheng Q, Chen W, Xu H, Li H, Luo J, Yang R, Mao X, Wang S, Chen T, Lee LP, Liu F. Interaction network of extracellular vesicles building universal analysis via eye tears: iNEBULA. Sci Adv. 2023;9(11):eadg1137.点击"阅读原文"

IRVINE, CA / ACCESSWIRE / May 4, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 third quarter ended March 31, 2023. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2023 with the Securities and Exchange Commission today. Quarter Ended March 31, 2023 Net sales for the three months ended March 31, 2023, increased $3.8 million, or 41%, to $13.1 million from $9.3 million for the three months ended March 31, 2022, due primarily to increased repair revenue of $3.2 million related to an enhanced repair program launched this fiscal year to upgrade the handpiece we sell our largest customer to its most current generation. Gross profit for the three months ended March 31, 2023, increased $953,000, or 33%, to $3.8 million from $2.9 million for the same period in fiscal 2022. The gross profit increase is consistent with our increase in net sales and is benefited by our resolution and agreement with our largest customer related to previously upgraded repairs. Additionally, we have continued to experience higher costs across much of our supply chain. Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended March 31, 2023, decreased slightly, by 5%, compared to the same period in fiscal 2022 mostly due to reduced general and administration expenses. Net income for the quarter ended March 31, 2023, was $1.3 million, or $0.36 per diluted share, compared to $462,000, or $0.12 per diluted share, for the corresponding quarter in fiscal 2022. Nine Months Ended March 31, 2023 Net sales for the nine months ended March 31, 2023, increased $6.0 million, or 20%, to $35.4 million from $29.4 million for the nine months ended March 31, 2022, due to increased repair revenue of $4.3 million related to the enhanced repair program described above, as well as an increase of $1.5 million in billable non-recurring engineering projects. Gross profit for the nine months ended March 31, 2023, decreased $299,000, or 3%, compared to the same period in fiscal 2022. The gross profit decline for the nine months ended March 31, 2023, is due in part to the enhanced repair program described above, which includes the advance replacement of many costly components of the handpiece, as well as higher costs across much of our supply chain. Operating expenses (which include selling, general and administrative, and research and development expenses) for the nine months ended March 31, 2023, decreased 9% to $5.2 million from $5.7 million in the prior fiscal year's corresponding period, mostly due to reduced non-cash stock based compensation expense recorded in general and administrative expenses. Net income for the nine months ended March 31, 2023 was $3.3 million, or $0.89, per diluted share, compared to $2.5 million, or $0.65 per diluted share, for the corresponding period in fiscal 2022. CEO Comments "We are pleased with our third quarter results, as we continue to demonstrate our ability to grow revenue while controlling operating expenses," said the Company's President and Chief Executive Officer, Richard L. ("Rick") Van Kirk. "We are tracking toward another record fiscal year from a revenue perspective, and we expect to have completed the transfer of all of our assembly and repairs operations to the Franklin facility in the fourth quarter." About Pro-Dex, Inc.: Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also manufactures and sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at . Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, (including, but not limited to, the anticipated commencement of operations at the Franklin facility and expected fiscal year revenue), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission. (tables follow) PRO-DEX, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share amounts) March 31, 2023 June 30, 2022 ASSETS Current Assets: Cash and cash equivalents............................................... $ 2,088 $ 849 Investments.................................................................... 1,149 755 Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at March 31, 2023 and at June 30, 2022, respectively................................................. 10,565 15,384 Deferred costs............................................................... 279 710 Inventory....................................................................... 15,145 12,678 Prepaid expenses and other current assets........................ 1,919 790 Total current assets..................................................... 31,145 31,166 Land and building, net........................................................ 6,273 6,343 Equipment and leasehold improvements, net........................ 5,162 4,833 Right of use asset, net......................................................... 1,968 2,248 Intangibles, net.................................................................. 87 118 Deferred income taxes, net................................................. 764 797 Investments....................................................................... 1,534 1,779 Other assets....................................................................... 42 42 Total assets.................................................................... $ 46,975 $ 47,326 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable........................................................... $ 3,068 $ 3,761 Accrued expenses........................................................... 2,425 2,751 Deferred revenue............................................................ 57 1,013 Income taxes payable...................................................... 1,480 544 Note payable.................................................................. 3,114 3,285 Total current liabilities................................................ 10,144 11,354 Lease liability, net of current portion.................................. 1,745 2,054 Notes payable, net of current portion.................................. 9,247 10,250 Total non-current liabilities......................................... 10,992 12,304 Total liabilities............................................................... 21,136 23,658 Shareholders' equity: Common shares; no par value; 50,000,000 shares authorized; 3,545,309 and 3,596,131 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively................................................................ 6,585 7,682 Retained earnings .......................................................... 19,254 15,986 Total shareholders' equity........................................... 25,839 23,668 Total liabilities and shareholders' equity................... $ 46,975 $ 47,326 PRO-DEX, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited) (In thousands, except per share amounts) Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Net sales................................................................. $ 13,079 $ 9,265 $ 35,448 $ 29,426 Cost of sales .......................................................... 9,268 6,407 26,058 19,737 Gross profit............................................................. 3,811 2,858 9,390 9,689 Operating expenses: Selling expenses..................................................... 24 20 146 79 General and administrative expenses................... 1,009 1,145 2,983 3,402 Loss on disposal of equipment.............................. - 14 - 14 Research and development costs.......................... 713 658 2,109 2,254 Total operating expenses....................................... 1,746 1,837 5,238 5,749 Operating income................................................... 2,065 1,021 4,152 3,940 Interest expense...................................................... (131 ) (112 ) (389 ) (349 ) Unrealized gain (loss) on marketable equity investments........................................................ (177 ) (275 ) 231 (427 ) Interest and other income...................................... 11 - 235 50 Gain on sale of investments.................................. - - 7 - Income before income taxes................................. 1,768 634 4,236 3,214 Income tax expense............................................... (455 ) (172 ) (968 ) (764 ) Net income............................................................. $ 1,313 $ 462 $ 3,268 $ 2,450 Basic net income per share: Net income......................................................... $ 0.37 $ 0.13 $ 0.91 $ 0.67 Diluted net income per share: Net income........................................................ $ 0.36 $ 0.12 $ 0.89 $ 0.65 Weighted average common shares outstanding: Basic................................................................... 3,548 3,626 3,580 3,645 Diluted................................................................ 3,623 3,749 3,656 3,774 Common shares outstanding................................. 3,545 3,618 3,545 3,618 CONTACT: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 SOURCE: Pro-Dex, Inc. View source version on accesswire.com: